{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.18","statisticalMethod":"Kruskal-Wallis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.0","upperLimit":"35.0","value":"7.5"},{"groupId":"OG001","lowerLimit":"-15.0","upperLimit":"25.5","value":"4.5"},{"groupId":"OG002","lowerLimit":"14.0","upperLimit":"36.0","value":"26.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"S-1,25-vitD, change from baseline at 48 weeks.","dispersionType":"Inter-Quartile Range","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final blood-sampling.","reportingStatus":"POSTED","timeFrame":"Change from baseline at 48 weeks reported.","title":"Changes in s-1,25-vitamin D","type":"SECONDARY","unitOfMeasure":"pmol/l"}